Efferon therapy

16/02/2026

What We Still Don’t Know About Surgical Sepsis

13/02/2026

Efferon LPS is now approved in Thailand 🇹🇭

We are proud to announce that the Efferon LPS device has received official authorization in Thailand. This makes the 40th country where Efferon is available!

Together with our partner, NorrDia AB, we are committed to supporting and developing new regions to achieve sustainable, long-term growth and bring our innovative therapies to patients in need.

is a next-generation extracorporeal blood adsorber designed to remove endotoxin and inflammatory mediators. The device is manufactured in the European Union and holds a CE certificate in accordance with the MDR regulation, reflecting compliance with current European standards.

02/02/2026

Prof. Ioannis Griveas (NIMTS Athens, Greece) is convinced: in sepsis, early initiation of hemoadsorption and enough time for each session is essential.

He discusses when to start , why the number of procedures cannot be standardized, and why clinical evaluation must often guide decisions when laboratory data arrive too late in the early phase of .

We thank Prof. Griveas for openly sharing clinical experience and reflections with the critical care community.

In this interview, Prof. Ioannis Griveas shares practical insights into hemoadsorption therapy: when to start, how long to treat, how many sessions are need...

30/01/2026

Cost-effectiveness of sepsis and hemoadsorption

29/01/2026

We are proud to share that the first sepsis patient in the Baltic countries has been treated with Efferon.

This clinical case from Riga once again confirms the role of multimodal as part of comprehensive critical care when conventional therapy alone is insufficient.

Step by step, advanced extracorporeal technologies such as are becoming accessible where they are truly needed.

We sincerely thank Prof. Olegs Sabelnikovs, Darja Smirnova, Society of Anaesthesiologists and Reanimatologists of Latvia and the entire clinical team for their trust, courage, and outstanding work.

22/01/2026

Dr. George Dimopoulos (Hospital Medical School, Athens) shares his clinical perspective on hemoadsorption in sepsis, focusing on what matters most at the bedside: clinical outcomes.

He discusses why rapid hemodynamic improvement is a key decision driver, how reduced vasopressor need and improved oxygenation shape his assessment, and why biomarkers alone should never replace clinical judgment.

This conversation continues our interview series with experienced intensivists, centered on real-world decision-making in high-acuity critical care.

We sincerely thank Dr. Dimopoulos for sharing his insights and experience with the critical care community.

Dr. George Dimopoulos (Hospital Medical School, Athens) shares his clinical perspective on hemoadsorption in sepsis, focusing on what matters most at the bed...

19/01/2026

Professor Thomas Rimmelé (Nice University Hospital, France) addresses key questions around in : when it may truly make a difference, how to approach patient selection, and what can realistically expect from adjunctive purification in daily practice.

15/01/2026

Efferon is available now in the Baltic Region: the first case in the Baltic countries presented by Paula Stradiņa Clinical University Hospital

At the annual conference of the Society of Anaesthesiologists and Reanimatologists of Latvia ( ) on December 12, Dr. Darja Smirnova presented the first successful clinical case of in treating a patient with septic shock. The treatment was conducted under the guidance of the Vice-President of the Latvian Society of Anaesthesiology and Reanimatology Prof. Olegs Sabelnikovs at the Paula Stradiņa Clinical University Hospital.

According to the data presented, therapy was associated with a rapid and sustained clinical response. The level of inflammatory biomarkers decreased significantly, which was accompanied by rapid hemodynamic stabilization, restoration of organ function and respiratory function improvement. The patient was successfully weaned from vasopressor support, discharged from intensive care within 4 days, and later released from hospital, indicating a favorable clinical course following therapy.

Another successful outcome serves as a powerful example of the therapy's clinical impact. Efferon hemoadsorption therapy is now available in more than 35 countries in the world, including Estonia and Latvia, expanding access to this advanced critical care tool.

We express our deep gratitude to Prof. Olegs Sabelnikovs for the trust and professionalism. We also want to acknowledge LARA's vital role in helping us bring this advanced critical care tool to more clinicians and patients in the Baltic region.

14/01/2026

Professor Thomas Rimmelé (Nice University Hospital, France) addresses key questions around in sepsis: when it may truly make a difference, how to approach patient selection, and what clinicians can realistically expect from adjunctive blood purification in daily practice.

Every case of in the ICU is full of critical decisions, complex physiology, and the constant question: are we doing enough for these patients? This conversation opens a new interview series with experienced clinicians from around the world, focused on real-world decision-making in high-acuity critical care beyond protocols and publications.

We sincerely thank Professor Rimmelé for sharing his experience and practical insights with the critical care community.

In this interview, Professor Thomas Rimmelé (Nice University Hospital, France) addresses key questions around hemoadsorption in sepsis: when it may truly mak...

14/01/2026

Sepsis: 11 Million Deaths Every Year

12/01/2026

Sepsis accounts for up to 20% of all deaths worldwide.

Behind the dry figures are real patients, overwhelmed healthcare systems, and the urgent need for earlier recognition and effective supportive strategies.

We are highlighiting key global facts about to help frame the scale of the problem and the importance of timely, multimodal approaches in .

We thank Our World in Data and the European Sepsis Alliance for making this data accessible and transparent.

08/01/2026

As we’re kicking off 2026, remains focused on supporting critically ill patients through extracorporeal blood purification.

Sepsis and septic shock continue to place an enormous burden on ICUs worldwide. Beyond being a leading cause of mortality, is also one of the most resource-intensive conditions in critical care. Despite advances in antimicrobial therapy and organ support, outcomes are still largely determined by the speed and effectiveness of early intervention.

Early modulation of the inflammatory cascade continues to be a key part of critical care strategy, and multimodal is increasingly becoming part of this approach in high-acuity settings.

Efferon LPS is a next-generation extracorporeal blood adsorber designed to remove endotoxin and inflammatory mediators. The device is manufactured in the European Union and holds a CE certificate in accordance with the MDR regulation, reflecting compliance with current European standards.

The first-ever multimodal hemoadsorption technology, designed and manufactured in Europe to support patients with sepsis and septic shock.Our devices Efferon...